粪便钙卫蛋白有效排除789例有/无报警症状的症状性年轻成人中的炎症性肠病:一项英国前瞻性初级保健队列研究
该前瞻性队列研究纳入789例18-46岁疑似炎症性肠病(IBD)的年轻成人,在49家全科诊所接受粪便钙卫蛋白检测(以≥100 μg/g为阳性),以12个月内的初级和二级医疗记录为参考标准。结果显示,无论有无胃肠道报警症状,钙卫蛋白区分IBD与功能性肠病的阴性预测值均很高(有报警症状98%,无报警症状99%),并估计可减少279次转诊、每例患者节省160英镑。
要点
- 在疑似IBD的年轻成人中,钙卫蛋白检测的阴性预测值在有报警症状者为98%、无报警症状者为99%。
- 有报警症状者钙卫蛋白阳性预测值为50%,无报警症状者为27%。
- 钙卫蛋白检测可减少二级医疗转诊并降低诊断相关医疗费用。
核心结论
- 在初级保健中,对疑似IBD的年轻成人进行钙卫蛋白检测可准确区分IBD与功能性肠病,即使患者有胃肠道报警症状,并可减少二级医疗转诊和诊断相关医疗费用。
研究设计与样本
- 前瞻性队列研究,纳入789例18-46岁因疑似IBD接受钙卫蛋白检测的年轻成人,来自49家当地全科诊所,检测时间为2014年1月至2016年5月,共1053次检测。
- 以钙卫蛋白≥100 μg/g为阳性,以检测后12个月内的初级和二级医疗记录为参考标准。
主要发现
- 39%(308/789)患者报告胃肠道报警症状,6%(50/789)接受检测的患者被诊断为IBD。
- 有胃肠道报警症状者,钙卫蛋白区分IBD与功能性肠病的阳性预测值为50%(95% CI 36%-64%),阴性预测值为98%(96%-100%)。
- 无胃肠道报警症状者,钙卫蛋白区分IBD与功能性肠病的阳性预测值为27%(16%-41%),阴性预测值为99%(98%-100%)。
- 估计可节省279次转诊,每例患者节省160英镑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary care faecal calprotectin testing distinguishes inflammatory bowel disease (IBD) from functional gut disorder in young patients presenting with abdominal symptoms; however, previous evaluations have excluded patients with alarm symptoms. AIMS: We sought to evaluate the diagnostic accuracy of calprotectin to distinguish IBD from functional gut disorder in young adults in whom general practitioners (GPs) suspected IBD; including patients reporting gastrointestinal alarm symptoms. We hypothesised that calprotectin would reduce secondary care referrals and healthcare costs. METHODS: We undertook a prospective cohort study of 789 young adults (18-46 years old) presenting with gastrointestinal symptoms to 49 local general practices that had undergone calprotectin testing (1053 tests: between Jan 2014 and May 2016) because of suspected IBD. We considered calprotectin levels of ≥100 μg/g positive. Primary and secondary care records over 12 months from the point of calprotectin testing were used as the reference standard. RESULTS: Overall, 39% (308/789) patients reported gastrointestinal alarm symptoms and 6% (50/789) tested patients were diagnosed with IBD. The positive and negative predictive values of calprotectin testing for distinguishing IBD from functional gut disorder in patients with gastrointestinal alarm symptoms were 50% (95% CI 36%-64%) and 98% (96%-100%): and in patients without gastrointestinal alarm symptoms were 27% (16%-41%) and 99% (98%-100%), respectively. We estimate savings of 279 referrals and £160 per patient. CONCLUSIONS: Calprotectin testing of young adults with suspected IBD in primary care accurately distinguishes IBD from functional gut disorder, even in patients with gastrointestinal alarm symptoms and reduces secondary care referrals and diagnostic healthcare costs.
引用
- Walker GJ, Moore L, Heerasing N, et al. Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Aliment Pharmacol Ther. 2018. PMID: 29508423. doi:10.1111/apt.14563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。